The implant mimics the natural motion of a native disc and is indicated as an alternative to cervical fusion. It received FDA approval in 2019 and also has a CE mark in the European union.
Earlier this year, three- and four- year data showed the effectiveness of M6-C at the single level, and a U.S. investigational device exemption two-level study began in August.
“The M6-C artificial cervical disc is continuing to establish a market-leading position globally with more than 60,000 devices implanted worldwide,” Orthofix President of Global Spine Kevin Kenny stated in a news release from the company. “We are pleased to see the continued adoption of this state-of-the-art technology as our international success translates into the U.S. market.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
